Header

GYN: Ovarian, Fallopian, Peritoneal Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 21 trials

A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 3

Protocol Number: 14-050

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Hospitalized patients with pancreatic, stomach, ovarian or non-small lung cancer, or non-Hodgkin's lymphoma and who are at high risk for a venous thromboembolisn will be randomized to standard ...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Other Cancers, Stomach Cancer, Non-Hodgkin's Lymphoma, Pancreatic Cancer

Phase: 2

Protocol Number: 15-547

A Phase II Study Of Nivolumab/ Bevacizumab

This research study is evaluating two drugs called Nivolumab and Bevacizumab as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 2

Protocol Number: 16-263

The Women Choosing Surgical Prevention (WISP) Trial

The goal of this clinical research study is to compare the changes in female sexual function between patients having interval salpingectomy with delayed oophorectomy (ISDO) with those having risk-r...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 2

Protocol Number: 16-389

Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer

The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation. Additionally, this st...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1 / 2

Protocol Number: 16-550

Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum Sensitive Ovarian Cancer

Part 1 (Phase 1): safety and tolerability of bevacizumab-Niraparib combination Part 2 (Randomized Phase 2): to compare Progression-Free Survival (PFS) PARP inhibitors are active as monotherapy to t...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1 / 2

Protocol Number: 16-250

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

This research study is evaluating a drug called omalizumab (brand name 'Xolair') as a potential treatment to be used in conjunction with drug desensitization to prevent reactions from recur...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1

Protocol Number: 13-485

Study of IMGN853 in Comb. With Bevacizumab, Carboplatin, PLD or Pembrolizumab in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer

This is a phase 1b study to assess the safety, tolerability, and preliminary anti-tumor activity of IMGN853 when administered with chemotherapy. Patients will be assigned to one of four regimens: I...

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1

Protocol Number:

Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

This phase I trial studies the side effects and best dose of olaparib and Hsp90 inhibitor AT13387 when given together in treating patients with solid tumors that have spread to other places in the ...

Diagnosis: Breast: Metastatic, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1

Protocol Number: 17-715

AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase II Study of AZD1775 plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Patients will receive AZD1775 plus carboplatin or...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 14-547

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

This is a Phase 1/2, open label study that will be conducted in 2 parts. The first part of the study (Phase 1) will consist of a dose-escalation assessment of the safety and tolerability of epacado...

Diagnosis: Head and Neck Cancer, Brain/Neuro Cancer: Recurrent Glioblastoma, Lung Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 15-484

Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer ...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Breast: Metastatic

Phase:

Protocol Number: 15-550

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have prev...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 16-410

The HOPE Trial:Helping Our Patients Excel

This research study is evaluating a new smartphone application named the "Helping Our Patients Excel (HOPE)" app with Fitbit devices. The HOPE app was designed to learn about improving qu...

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Cervical Cancer

Phase:

Protocol Number: 16-477

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alon...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 16-513

PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platin...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 16-131

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high g...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 16-613

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

This is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelia...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 16-526

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a po...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Breast: Metastatic

Phase:

Protocol Number: 17-285

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

This is Phase IB, open label, non-randomized study designed to investigate the dose, safety, pharmacokinetics and anti-tumor activity of RO6870810 in combination with a fixed dose of atezolizumab. ...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Breast: Early Stage Disease

Phase:

Protocol Number: 17-534

Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer

This research study will test whether using wearable fitness trackers with or without a social incentive, delivered through a game-based mobile health intervention, increases physical activity and ...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 17-361

'